Company intelligence / Profile preview

Velvet Management

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Velvet Therapeutics is a private biotechnology company focused on developing innovative therapies for rare diseases and metabolic disorders. Founded by a team of experienced executives from Akcea Therapeutics and Ionis Pharmaceuticals, the company leverages deep expertise in antisense technology and metabolic pathways. Velvet Therapeutics aims to address significant unmet medical needs by targeting specific genetic and molecular drivers of disease. The company's leadership team has a proven track record in drug development and commercialization within the rare disease space.

Therapeutic areas: Rare DiseasesGastroenterologyMetabolic Disorders
Modalities: Small moleculeAntisense oligonucleotide
Industry: Biotech

Beyond the preview

Go deeper on Velvet Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Velvet Management.

Explore the full profile